Yukio Hosomi
- Oncology top 1%
- Lung Cancer Research Studies 68
- Cancer Immunotherapy and Biomarkers 33
- Colorectal Cancer Treatments and Studies 32
-
- Lung Cancer Treatments and Mutations 110
- Lung Cancer Diagnosis and Treatment 45
- Gastric Cancer Management and Outcomes 18
- Cancer Research top 5%
- Neurology top 5%
- Myasthenia Gravis and Thymoma 24
- Immunology top 10%
-
- Cancer therapeutics and mechanisms 13
Yukio Hosomi
177 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 2.5k
- Pulmonary and Respiratory Medicine 2.1k
- Cancer Research 429
- Neurology 350
- Immunology 285
Countries citing papers authored by Yukio Hosomi
This map shows the geographic impact of Yukio Hosomi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yukio Hosomi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yukio Hosomi more than expected).
Fields of papers citing papers by Yukio Hosomi
This network shows the impact of papers produced by Yukio Hosomi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yukio Hosomi. The network helps show where Yukio Hosomi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yukio Hosomi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 3 | |
| 6 | 2024 | 0 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 1 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 9 | |
| 11 | 2023 | 7 | |
| 12 | 2023 | 3 | |
| 13 | 2022 | 53 | |
| 14 | 2022 | 5 | |
| 15 | 2021 | 4 | |
| 16 | 2020 | 216 | |
| 17 | 2020 | 14 | |
| 18 | 2019 | 104 | |
| 19 | 2017 | 1 | |
| 20 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studybreakdown → | 2014 | 561 |
About Yukio Hosomi
Yukio Hosomi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Neurology, having authored 189 papers that have together received 3.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (110 papers), Lung Cancer Research Studies (68 papers), Lung Cancer Diagnosis and Treatment (45 papers), Cancer Immunotherapy and Biomarkers (33 papers), Colorectal Cancer Treatments and Studies (32 papers), Myasthenia Gravis and Thymoma (24 papers), Gastric Cancer Management and Outcomes (18 papers) and Cancer therapeutics and mechanisms (13 papers). The work is most often cited by research in Oncology (2.5k citations), Pulmonary and Respiratory Medicine (2.1k citations) and Cancer Research (429 citations). Yukio Hosomi has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include Yusuke Okuma, Taiki Hakozaki, Terufumi Kato, Makoto Nishio, Tatsuru Okamura, Kageaki Watanabe, Nobuyuki Yamamoto, Takashi Seto, Kazuhiko Nakagawa and Akihiko Gemma. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, Japanese Journal of Clinical Oncology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.